EMEA-001442-PIP01-13

Key facts

Active substance
  • Raltegravir
  • lamivudine
Therapeutic area
Infectious diseases
Decision number
P/0001/2014
PIP number
EMEA-001442-PIP01-13
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
Merck Sharp & Dohme (Europe), Inc. 
Belgium 
Tel: +33 180 464738
E-mail: pip.information@merck.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance procedure number
EMEA-C-001442-PIP01-13
Compliance opinion date
21/03/2014
Compliance outcome
positive

Decision

How useful was this page?

Add your rating